disease modifying antirheumatic drugs

disease modifying antirheumatic drugs (DMARD),

agents that apparently alter the course and progression of rheumatoid arthritis, as opposed to more rapidly acting substances that suppress inflammation and decrease pain, but do not prevent cartilage or bone erosion or progressive disability.
References in periodicals archive ?
KEVZARA is approved to treat adults with moderately to severely active rheumatoid arthritis (RA) who have an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), added the company.
The terrible side effects of the non-steroidal antiinflammatory drugs(NSAID) used to treat Rheumatoid arthritis (RA) include heartburn, stomach problems, ulcers and even bleeding, while the more effective disease modifying antirheumatic drugs (DMARD) can cause high blood pressure, cataracts, weight gain, sleep problems, muscle loss, bruising and thinning of the bones (osteoporosis).
Methotrexate (MTX) is the anchor treatment for rheumatoid arthritis and similar inflammatory conditions and has been very thoroughly studied in many different patient populations, as monotherapy and in combination with various other disease modifying antirheumatic drugs and biologic agents.
This study also underlines the importance of rigorous control of inflammation with disease modifying antirheumatic drugs, not only for the management of joint symptoms but also to reduce the need for drugs with potential adverse cardiovascular effects and, ultimately to diminish the inflammation driven atherothrombotic process," they emphasized.
fter five years, 97 pc of the patients had been treated with disease modifying antirheumatic drugs (DMARDs), reducing both the chemical markers of inflammation and the physical appearance of their arthritis.
The good news is that drug treatments are available to help ease the pain, including nonsteroidal anti-inflammatory drugs, analgesic drugs and disease modifying antirheumatic drugs.
Kineret is intended for patients at least 18 years of age who have not responded to one or more drugs referred to as disease modifying antirheumatic drugs.
Food and Drug Administration has approved Kineret(TM) (anakinra) for the reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) in adult patients who have failed one or more disease modifying antirheumatic drugs (DMARDs).
The US FDA has approved the partnership's Kevzara (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX).
Kineret is for patients at least 18 years of age who have not responded to one or more drugs referred to as DMARDs or disease modifying antirheumatic drugs.

Full browser ?